Position in APLS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$301,725
New position
Shares Held
7,500
first reported quarter
Ownership
0.006%
of shares outstanding
% of Portfolio
0.43%
of 13F equity value
Holder Rank
#230
of 320 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026FIFTH LANE CAPITAL, LP holds $8,309,558 across 11 Biotechnology names. APLS ranks #7 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
|
31,044 | $3,564,472 | |
| 2 | ABVX |
Abivax S.A.
|
15,858 | $1,765,788 | |
| 3 | NKTR |
Nektar Therapeutics
|
12,000 | $863,400 | |
| 4 | RNA |
Atrium Therapeutics, Inc.
|
35,999 | $481,306 | |
| 5 | TERN |
Terns Pharmaceuticals, Inc.
|
8,000 | $421,760 | |
| 6 | RLMD |
Relmada Therapeutics, Inc.
|
45,000 | $313,200 | |
| 7 | APLS |
Apellis Pharmaceuticals, Inc.
This page
|
7,500 | $301,725 | |
| 8 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
7,161 | $260,087 |
All Filings in APLS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $301,725 | 7,500 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||